BENNETT C FRANK 4

What Happened
Bennett C. Frank, EVP and Chief Scientific Officer of Ionis Pharmaceuticals (IONS), acquired 261 shares on February 27, 2026 at $48.87 per share, for a total value of $12,754. The transaction is reported as an "other acquisition" under the filing and represents a purchase through the company's employee stock purchase plan.

Key Details

• Transaction date: 2026-02-27; price: $48.87 per share; total cost: $12,754.
• Transaction code: J (other acquisition); shares were purchased under the Ionis Amended and Restated 2000 Employee Stock Purchase Plan (footnote F1).
• Lock-up/restriction: these shares may not be sold until August 27, 2026 (per filing).
• Shares owned after transaction: not disclosed in the provided excerpt of the Form 4.
• Filing date: 2026-03-03 — this filing was submitted within the typical two-business-day window and is not marked late.

Context
This was a purchase through an employee stock purchase plan (ESPP), a routine benefit for employees that often involves payroll deductions and mandatory holding periods. Such purchases can be informative but are commonly part of compensation programs and do not by themselves indicate management’s broader market view.